Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis

BACKGROUND: COVID-19 vaccination is essential. However, no study has reported adverse events (AEs) after ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease (ESRD) on hemodialysis (HD). This study investigated the AEs within 30-days after the first dose of ChAdOx1 nCoV19 (Oxford-Ast...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, I-Ning, Lu, Chin-Li, Tang, Hung-Jen, Kuo, Yu-Chi, Tsai, Li-Hwa, Tu, Kuan Chieh, Wang, Jhi-Joung, Chien, Chih-Chiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462771/
https://www.ncbi.nlm.nih.gov/pubmed/36084024
http://dx.doi.org/10.1371/journal.pone.0273676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462771/
https://www.ncbi.nlm.nih.gov/pubmed/36084024
http://dx.doi.org/10.1371/journal.pone.0273676

Ejemplares similares